The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysisAlbert DeFelice, Raymond J. Lipicky, Morris Gordon et al.|Journal of Human Hypertension|2008Cited by 23
Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular riskEric P. Brass, William R. Hiatt, Robert A. Lewis et al.|Clinical Pharmacology & Therapeutics|2006Cited by 22